In the afternoon trade, the healthcare stocks were mixed, with the NYSE Healthcare Sector Index trading 0.2% in red and most shares of healthcare companies from the S&P 500 gaining 0.1% as a group.
Among particular companies, Northwest Biotherapeutics (NWBO) gained ground on Monday following the oncology care company announcing that it has received some regulatory approvals from German authorities for its DCVax-L treatment for glioma brain cancer.
The Paul Ehrlich Institute accepted a “Hospital Exemption” early access program for Northwest, under Section 4b of German Drug Law, which allows the company to provide the experimental drug for the treatment of both Glioblastoma multiforme and lower grade gliomas outside clinical trials. Moreover, the program allows the company to charge a full price for the medication. The DCVax-L has also been cleared for reimbursement. The initial approvals will be effective for the next five years.
So far, the stock NWBO surged by around 13% to $6.83, getting close to a new intra-day high. The stock has a 52-week range of $2.98 to $20.00.
NWBO is not the only company on the radars today, RGDO, gained around 23.3% after the U.S. Food and Drug Administration designatesd the company’s REG1 anticoagulant therapy with fast-track development status to be used in patients with coronary artery disease in percutaneous coronary interventions. On the other hand, BONE lost 4.0% amid closing on $4 million worth of additional funding from OrbiMed in exchange for 1.5 mln of its shares. Other terms of the deal remain unchanged from the companies’ $20 million term loan signed in August 2012.
Suggested Reading: Best European NBA Players
